5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction

5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction

Although 1-3,4-dihydroxyphenylalanine (L-DOPA) is the mainstay therapy for treating Parkinson's disease (PD), its long-term administration is accompanied by the development of motor complications, particularly L-DOPA induced dyskinesia (LID), that dramatically affects patients' quality of...

Full description

Bibliographic Details
Main Authors: Silvia Fanni, Simona Scheggi, Francesca Rossi, Elisabetta Tronci, Francesco Traccis, Roberto Stancampiano, Maria Graziella De Montis, Paola Devoto, Carla Gambarana, Marco Bortolato, Roberto Frau, Manolo Carta
Format: Article
Language:English
Published: Elsevier 2019-01-01
Series:Neurobiology of Disease
Subjects:
L-DOPA
5alpha-reductase
Dutasteride
Parkinson's disease
Dyskinesia
6-OHDA
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996118306053

Internet

http://www.sciencedirect.com/science/article/pii/S0969996118306053

Similar Items